These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32404427)

  • 1. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
    Cubria MB; Suarez S; Masoudi A; Oftadeh R; Kamalapathy P; DuBose A; Erdos MR; Cabral WA; Karim L; Collins FS; Snyder BD; Nazarian A
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12029-12040. PubMed ID: 32404427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
    Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
    Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
    Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
    Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
    Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac and skeletal muscle manifestations in the G608G mouse model of Hutchinson-Gilford progeria syndrome.
    Hong Y; Rannou A; Manriquez N; Antich J; Liu W; Fournier M; Omidfar A; Rogers RG
    Aging Cell; 2024 Oct; 23(10):e14259. PubMed ID: 38961628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
    JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
    Gordon LB; Massaro J; D'Agostino RB; Campbell SE; Brazier J; Brown WT; Kleinman ME; Kieran MW;
    Circulation; 2014 Jul; 130(1):27-34. PubMed ID: 24795390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone dysplasia in Hutchinson-Gilford progeria syndrome is associated with dysregulated differentiation and function of bone cell populations.
    Cabral WA; Stephan C; Terajima M; Thaivalappil AA; Blanchard O; Tavarez UL; Narisu N; Yan T; Wincovitch SM; Taga Y; Yamauchi M; Kozloff KM; Erdos MR; Collins FS
    Aging Cell; 2023 Sep; 22(9):e13903. PubMed ID: 37365004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
    Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
    Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
    Arnold R; Vehns E; Randl H; Djabali K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.
    Sagelius H; Rosengardten Y; Schmidt E; Sonnabend C; Rozell B; Eriksson M
    J Med Genet; 2008 Dec; 45(12):794-801. PubMed ID: 18708427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
    Murtada SI; Mikush N; Wang M; Ren P; Kawamura Y; Ramachandra AB; Li DS; Braddock DT; Tellides G; Gordon LB; Humphrey JD
    Elife; 2023 Mar; 12():. PubMed ID: 36930696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Qiao X; Fong LG; Young SG
    Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
    Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
    FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hutchinson-Gilford progeria syndrome: clinical findings in three patients carrying the G608G mutation in LMNA and review of the literature.
    Mazereeuw-Hautier J; Wilson LC; Mohammed S; Smallwood D; Shackleton S; Atherton DJ; Harper JI
    Br J Dermatol; 2007 Jun; 156(6):1308-14. PubMed ID: 17459035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the Hutchinson-Gilford progeria mutation during osteoblast development results in loss of osteocytes, irregular mineralization, and poor biomechanical properties.
    Schmidt E; Nilsson O; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
    J Biol Chem; 2012 Sep; 287(40):33512-22. PubMed ID: 22893709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
    Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
    Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.